半夏泻心汤加减联合化疗治疗Ⅲ期结肠癌的疗效。
Effect of a modified Banxia Xiexin decoction plus chemotherapy on stage Ⅲ colon cancer.
机构信息
Department of oncological surgery, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China.
Department of oncology, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, Beijing 100053, China.
出版信息
J Tradit Chin Med. 2019 Apr;39(2):251-257.
OBJECTIVE
To investigate the effect of a modified Banxia Xiexin decoction (MBXD) plus chemotherapy on postoperative adverse reaction in patients with stage Ⅲ colon cancer in patients whose symptoms were identified as cold-heat complicated pattern in terms of the theory of Traditional Chinese Medicine (TCM).
METHODS
A prospective non-randomized control study of patients with stage Ⅲ colon cancer in Beijing Shijitan Hospital and Guang'anmen Hospital between January 2012 and December 2013. A total of 80 patients were divided into experimental group (MBXD + chemotherapy) and control group (chemotherapy). The adverse reactions, life quality and disease-free survival (DFS) were compared between the two groups.
RESULTS
The cold-heat complex pattern was released in 94.3% of patients in experimental group whereas 62.2% in control group (P < 0.05). Life quality was improved in 24 vs 14 cases, stabilized in 9 vs 14 cases whereas decreased in 2 vs 15 cases in experimental group and control group, respectively (P < 0.05). The average DFS was 22.371 months in experimental group, while 13.932 months in control group (P < 0.05).
CONCLUSION
MBXD combined with chemotherapy may significantly relieve clinical symptoms, reduce chemotherapy associated adverse effects, improve life quality, and prolong DFS of patients with stage Ⅲ colon cancer (cold-heat complicated pattern).
目的
探讨半夏泻心汤加减联合化疗治疗Ⅲ期结肠癌患者术后不良反应的效果，这些患者的中医证候属于寒热错杂型。
方法
采用前瞻性非随机对照研究，纳入 2012 年 1 月至 2013 年 12 月在北京世纪坛医院和广安门医院就诊的Ⅲ期结肠癌患者。共纳入 80 例患者，分为实验组（MBXD+化疗）和对照组（化疗）。比较两组患者的不良反应、生活质量和无病生存（DFS）。
结果
实验组患者中寒热错杂证的缓解率为 94.3%，对照组为 62.2%（P<0.05）。实验组患者中生活质量改善的比例为 24%，稳定的比例为 9%，而对照组分别为 14%、14%和 15%（P<0.05）。实验组患者的平均 DFS 为 22.371 个月，对照组为 13.932 个月（P<0.05）。
结论
半夏泻心汤加减联合化疗可能显著缓解Ⅲ期结肠癌（寒热错杂型）患者的临床症状，减轻化疗相关不良反应，提高生活质量，延长无病生存时间。
Zotero 插件